伊尼妥单抗维持治疗HER2阳性乳腺癌1例

A case report of HER2 positive breast cancer traeted with inetetamab maintenance therapy

乳腺癌是全球女性最常见的恶性肿瘤之一,其发病率和致死率呈逐年上升的趋势。人表皮生长因子受体2(HER2)阳性乳腺癌是一种特殊类型的乳腺癌,具有较高的恶性程度且容易发生转移。目前针对HER2阳性乳腺癌,靶向治疗已成为一种重要的治疗方式。本文报道1例HER2阳性乳腺癌患者,该患者在接受右侧乳腺改良根治术后3年发生左侧乳腺转移,临床行左侧乳腺癌姑息手术,采用伊尼妥单抗维持治疗3年,目前病情稳定,治疗后未出现严重不良反应,疗效可期。

Breast cancer is one of the most common malignant tumors among women in the world,and its incidence and mortality are increasing year by year.Human epidermal growth factor receptor 2(HER2)positive breast cancer is a special type of breast cancer,which has a high degree of malignancy and is prone to metastasis.At present,targeted therapy has become an important treatment for HER2 positive breast cancer.This article reports on a patient with HER2-positive breast cancer.The patient developed left breast metastasis three years after modified radical mastectomy.Clinical palliative surgery was performed on the left breast cancer.Inetetamab was used for maintenance treatment for three years.At present,the condition is stable,and there is no serious adverse reaction after treatment.The curative effect can be expected.